| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability |
|
言語 |
en |
| 作成者 |
Ando, Yuwa
Yamauchi, Masami
Suehiro, Yosuke
Yamaoka, Kenji
Kosaka, Yumi
Fuji, Yasutomo
Uchikawa, Shinsuke
Kodama, Kenichiro
Morio, Kei
Fujino, Hatsue
Nakahara, Takashi
Ono, Atsushi
Murakami, Eisuke
Kawaoka, Tomokazu
Takahashi, Shoichi
Tsuge, Masataka
Hiramatsu, Akira
Imamura, Michio
Chayama, Kazuaki
Aikata, Hiroshi
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
This is a post-peer-review, pre-copyedit version of an article published in Clinical Journal of Gastroenterology. The final authenticated version is available online at: https://doi.org/10.1007/s12328-020-01099-3 |
| 権利情報 |
|
|
権利情報 |
This is not the published version. Please cite only the published version. この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。 |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Hepatocellular carcinoma |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Mismatch repair deficiency |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
MSI-high |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Immune checkpoint blockade |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
PD-L1 |
| 内容記述 |
|
|
内容記述 |
Hepatocellular carcinoma (HCC) has limited systemic treatment options and a poor prognosis. The immune checkpoint inhibitor pembrolizumab was recently approved for the treatment of solid tumors with microsatellite instability (MSI). However, its clinical utility for the management of HCC remains to be clarified. Here, we present a case of unresectable HCC with MSI that showed an impressive response to pembrolizumab treatment. A 64-year-old man with chronic HCV infection was diagnosed with a large HCC. His severe liver dysfunction and poor performance status prevented any treatment option other than sorafenib. However, sorafenib failed after a few days due to the rapid progression of the tumor. Based on the finding of MSI in a biopsy specimen, immunotherapy using pembrolizumab was initiated. A dramatic improvement in his general condition and a reduction in tumor size were observed after the initiation of pembrolizumab treatment. Among a cohort of 50 consecutive patients with advanced HCC who were refractory to standard systemic therapy, MSI was found only in the present case. Immune checkpoint blockade therapy induced prominent anti-tumor effects in HCC with MSI. Screening for defects in DNA mismatch repair function may be warranted in HCC patients despite the low frequency of MSI. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Springer |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AO |
|
出版タイプResource |
http://purl.org/coar/version/c_b1a7d7d4d402bcce |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s12328-020-01099-3 |
| 関連情報 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32020539 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s12328-020-01099-3 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1865-7257 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1865-7265 |
| 開始ページ |
|
|
開始ページ |
867 |
| 書誌情報 |
Clinical Journal of Gastroenterology
Clinical Journal of Gastroenterology
巻 13,
号 5,
p. 867-872,
発行日 2020-10
|
| 旧ID |
50461 |
| 備考 |
Post-print version/PDF may be used in an institutional repository after an embargo period of 12 months. |
ClinJGastroenterol_13_867.pdf (1.4 MB)
